Genmab A/S announced that it will discontinue the clinical development of acasunlimab, a bispecific antibody that had entered Phase 3 testing for non‑small cell lung cancer. The decision, made as part of a broader portfolio prioritization effort, frees up capital and clinical resources for the company’s high‑potential late‑stage assets, including epcoritamab (EPKINLY), petosemtamab, and the ADC Rina‑S (rinatabart sesutecan).
The move follows a 21% year‑over‑year increase in Genmab’s first‑nine‑month revenue, driven largely by higher royalties from DARZALEX and Kesimpta. Management confirmed that the discontinuation will not affect the company’s 2025 financial guidance, which remains in the $3.5‑$3.7 billion revenue range and a comparable operating margin outlook. By concentrating on assets that are closer to regulatory approval, Genmab aims to accelerate commercialization and strengthen its transition from a royalty collector to a fully integrated biopharma company.
CEO Jan van de Winkel explained that while acasunlimab’s earlier data were encouraging, the competitive landscape and the relative upside of the other programs warranted a shift in focus. “We are prioritizing investments where we can deliver the greatest benefit for patients and shareholders,” he said, noting that epcoritamab has already received approvals in several regions and petosemtamab holds two Breakthrough Therapy Designations. Rina‑S, a next‑generation ADC, has shown promising activity in advanced endometrial and ovarian cancers and received Fast Track designation for ovarian cancer from the FDA.
The decision underscores Genmab’s strategy to build a portfolio of assets that can generate product sales rather than relying primarily on royalty income. By reallocating resources to assets with clearer regulatory pathways and larger market opportunities, the company seeks to create a more robust and diversified revenue stream. The shift also aligns with Genmab’s planned acquisition of Merus, which would further expand its wholly‑owned pipeline and accelerate its integration into the biopharma value chain.
Overall, the discontinuation of acasunlimab signals a disciplined approach to capital allocation and portfolio management. It reflects Genmab’s confidence in the commercial potential of its remaining late‑stage programs and its commitment to maintaining a strong financial outlook while pursuing growth through product development rather than royalty collection.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.